<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396160</url>
  </required_header>
  <id_info>
    <org_study_id>SG-04</org_study_id>
    <nct_id>NCT02396160</nct_id>
  </id_info>
  <brief_title>The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence</brief_title>
  <official_title>The Effect of Urox™(Crateva, Horsetail and Lindera Combination) in the Treatment of Overactive Bladder and Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tasmania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seipel Group Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Endeavour College of Natural Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Queensland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control
      over 8 weeks, in a double blind, placebo controlled trial. 150 participants are being
      recruited, randomized and administered treatment or placebo for the period of 8 weeks after
      initial eligibility screening. Outcome measures include previously validated tools such as
      the 3 day symptom diary measuring self-recorded day frequency, nocturia, urgency and
      incontinence episodes. Quality of life improvements are being measured using the Incontinence
      Impact Questionnaire, Urinary Distress Inventory and the short version of the OverActive
      Bladder survey.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial consultations were held at either the Brisbane campus of the Endeavour College of
      Natural Medicine Naturopathic clinic or at Kelvin Grove Natural Medicine clinic, Brisbane.
      Follow up interviews are being conducted via telephone. To minimize dropout rates,
      participants are telephoned (as a reminder for the call and to complete the micturition
      diaries) approximately 1 week before the scheduled interview time and were intermittently
      called over the week following if they were unable to be reached at the scheduled interview
      time. Three attending clinicians interviewed trial participants, all having participated in
      interview training prior to any interviews being taken. The training was designed to ensure
      utility of a uniform and consistent approach regarding how questions were asked and how data
      was recorded.

      The week prior to an initial consultation participants were requested to complete a
      micturition diary and health related quality of life surveys, to serve as baseline measures.
      The attending clinician then also completed a clinical data sheet, at the time of the initial
      consultation, containing a range of questions including demographics, exercise, health
      history and habits, which will be used to control and correlate data variables. Any
      incomplete quality of life surveys at the outset were also completed at the first interview.

      Micturition diaries are collected by post at 2, 4 and 8 week intervals along with the
      completion of quality of life surveys and follow up clinical data sheet via telephone.
      Participants were asked to keep the micturition diary for 3 days prior to each consultation
      and were provided reply paid envelopes to return the surveys and unused capsules to assess
      compliance.

      For the primary outcome (day frequency) measure it was calculated that 90 participants
      equally divided into placebo and control were required to detect a difference of 1.6 urinary
      frequency episodes per day (2.7SD) between treatment and placebo groups, with a two-tailed
      alpha of 0.05 and a power of 80%. For total incontinence, 53 participants were required
      equally divided into each group to detect a difference of 1.2 episodes per day (2.2SD), while
      for urgency 54 was required in each group to detect a difference of 2 per day (3.7SD). To
      account for potential drop-outs and variations in presenting symptoms, a total of 150
      participants were recruited.

      Data for the two treatments will be compared using mixed effects ordered logistic regression
      adjusted for repeated measures (Stata, version 13.1, StataCorp, TX, USA). GraphPad Prism
      (version 6.00 for Windows, GraphPad Software, La Jolla California, USA) will be used to plot
      the data. Data (day frequency, night frequency, urgency and incontinence) will be evaluated
      by intention to treat analysis, with the last result brought forward for people who dropped
      out or were lost to follow-up. Variables selected for adjustment using backward stepwise
      regression from list including age, sex, water intake and diuretic use (p&lt;0.22 for covariate
      inclusion). Holm estimation test will be used to adjust p-values for repeated measures. Each
      analysis will only included participants who are symptomatic at baseline. For example, in
      relation to daytime urinary frequency - only participants with baseline of ≥10 will be
      included in the analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day Urinary Frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>Day urinary frequency as defined as the number of voluntary diurnal micturitions per day, recorded in a validated urinary diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nocturia Frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>Night time urinary frequency as defined as the number of voluntary nocturnal micturition's per day recorded in a validated urinary diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Urgency Frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>Urinary urgency as defined by number of urgency episodes per day recorded in a validated urinary diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urge Incontinence Frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>Urge incontinence as defined by number of incontinence episodes per day resulting from urinary urgency, recorded in a validated urinary diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress Incontinence Frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>Stress incontinence as defined by number of episodes of incontinence per day related to stress, recorded in a validated urinary diary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <condition>Urinary Frequency or Urgency Adverse Event</condition>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical placebo vegetarian capsule containing color-matched cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Urox</intervention_name>
    <description>Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria include symptoms of urinary frequency (at least ten times per day)
             and/or incontinence (at least nine episodes per week), provided they have experienced
             symptoms of OAB for at least 6 months.

        Exclusion Criteria:

          1. Recent surgery particularly hysterectomy or prolapse repair (within the last 12
             months)

          2. Recently undergone childbirth (within the last 12 months), or currently pregnant.

          3. Use of any natural therapies for bladder symptoms in the last month.

          4. Concomitant health conditions such as uncontrolled diabetes mellitus, heart disease,
             pancreatic, hepatic or renal disease, recurrent urinary tract infections, and chronic
             inflammatory conditions, which may otherwise affect outcomes.

          5. Currently being treated for mental health issues or psychiatric disturbances.

          6. Any individuals who are presently taking prescribed medication for incontinence or
             OAB.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niikee Schoendorfer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Queensland</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>April 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2016</results_first_posted>
  <last_update_submitted>April 3, 2016</last_update_submitted>
  <last_update_submitted_qc>April 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Queensland</investigator_affiliation>
    <investigator_full_name>Dr Niikee Schoendorfer</investigator_full_name>
    <investigator_title>Research Fellow</investigator_title>
  </responsible_party>
  <keyword>overactive bladder</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>nocturia</keyword>
  <keyword>urinary frequency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>As data was analysed de-identified, it is not possible to have individual participant data available associated with their name and details.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Urox: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>identical placebo vegetarian capsule containing color-matched cellulose
Placebo: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This data includes all those who met criteria (minimum of 2 of the following symptoms per day for 6 months - Urinary Day Frequency ≥10 daytime micturitions; Nocturia ≥2 night time micturitions; Urinary Urgency ≥2 episodes and/or Incontinence ≥1 episode) and were entered into randomisation at the commencement of their enrollment into the study</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Urox: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>identical placebo vegetarian capsule containing color-matched cellulose
Placebo: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.21" spread="12.11"/>
                    <measurement group_id="B2" value="62.26" spread="13.87"/>
                    <measurement group_id="B3" value="63.23" spread="13.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.90" spread="18.78"/>
                    <measurement group_id="B2" value="79.73" spread="22.74"/>
                    <measurement group_id="B3" value="79.82" spread="20.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Day urinary frequency</title>
          <description>number of participants ≥10 daytime micturitions per day</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Night urinary frequency</title>
          <description>number of participants ≥2 nocturnal micturitions per night</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urgency</title>
          <description>number of participants ≥2 urgency micturitions per day</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urge incontinence</title>
          <description>number of participants ≥1 urge incontinent episode per day</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stress incontinence</title>
          <description>number of participants ≥1 stress incontinent episodes per day</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any incontinence</title>
          <description>number of participants ≥1 any incontinence episodes per day</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2 symptoms</title>
          <description>number of participants reporting meeting 2 symptom criteria per day</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>3 symptoms</title>
          <description>number of participants reporting meeting 3 symptom criteria per day</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>4 symptoms</title>
          <description>number of participants reporting meeting 4 symptom criteria per day</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Day Urinary Frequency</title>
        <description>Day urinary frequency as defined as the number of voluntary diurnal micturitions per day, recorded in a validated urinary diary</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis includes participants who met the criteria for this outcome being day urination frequency ≥10 daytime micturitions per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Urox: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebo vegetarian capsule containing color-matched cellulose
Placebo: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Day Urinary Frequency</title>
          <description>Day urinary frequency as defined as the number of voluntary diurnal micturitions per day, recorded in a validated urinary diary</description>
          <population>Analysis includes participants who met the criteria for this outcome being day urination frequency ≥10 daytime micturitions per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
          <units>number of diurnal micturitions per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68" lower_limit="7.46" upper_limit="7.91"/>
                    <measurement group_id="O2" value="10.95" lower_limit="10.70" upper_limit="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Urgency Frequency</title>
        <description>Urinary urgency as defined by number of urgency episodes per day recorded in a validated urinary diary</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis includes participants who met the criteria for this outcome being urgency urination frequency ≥1 per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Urox: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebo vegetarian capsule containing color-matched cellulose
Placebo: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Urgency Frequency</title>
          <description>Urinary urgency as defined by number of urgency episodes per day recorded in a validated urinary diary</description>
          <population>Analysis includes participants who met the criteria for this outcome being urgency urination frequency ≥1 per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
          <units>number of urgency episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.28" upper_limit="1.71"/>
                    <measurement group_id="O2" value="3.92" lower_limit="3.65" upper_limit="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urge Incontinence Frequency</title>
        <description>Urge incontinence as defined by number of incontinence episodes per day resulting from urinary urgency, recorded in a validated urinary diary</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis includes participants who met the criteria for this outcome being urge incontinent frequency ≥1 per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Urox: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebo vegetarian capsule containing color-matched cellulose
Placebo: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Urge Incontinence Frequency</title>
          <description>Urge incontinence as defined by number of incontinence episodes per day resulting from urinary urgency, recorded in a validated urinary diary</description>
          <population>Analysis includes participants who met the criteria for this outcome being urge incontinent frequency ≥1 per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
          <units>number of urge incontinence episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="0.89" upper_limit="1.54"/>
                    <measurement group_id="O2" value="2.36" lower_limit="2.07" upper_limit="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nocturia Frequency</title>
        <description>Night time urinary frequency as defined as the number of voluntary nocturnal micturition's per day recorded in a validated urinary diary</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis includes participants who met the criteria for this outcome being nocturnal frequency ≥2 per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Urox: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebo vegetarian capsule containing color-matched cellulose
Placebo: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturia Frequency</title>
          <description>Night time urinary frequency as defined as the number of voluntary nocturnal micturition's per day recorded in a validated urinary diary</description>
          <population>Analysis includes participants who met the criteria for this outcome being nocturnal frequency ≥2 per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
          <units>number of nocturnal micturitions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" lower_limit="2.02" upper_limit="2.29"/>
                    <measurement group_id="O2" value="3.11" lower_limit="2.98" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stress Incontinence Frequency</title>
        <description>Stress incontinence as defined by number of episodes of incontinence per day related to stress, recorded in a validated urinary diary</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis includes participants who met the criteria for this outcome being stress incontinence frequency ≥1 per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Urox: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebo vegetarian capsule containing color-matched cellulose
Placebo: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Stress Incontinence Frequency</title>
          <description>Stress incontinence as defined by number of episodes of incontinence per day related to stress, recorded in a validated urinary diary</description>
          <population>Analysis includes participants who met the criteria for this outcome being stress incontinence frequency ≥1 per day at baseline. Please note that not all participants in this study met the criteria for all outcomes, hence numbers in each section may seem incongruent with total study participants.</population>
          <units>Number of stress incontinence episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="0.47" upper_limit="0.86"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.26" upper_limit="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Urox: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>identical placebo vegetarian capsule containing color-matched cellulose
Placebo: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Episodes of diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Halitosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Worsened arthritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Worsened memory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Headache and worsened asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of this study include the relatively short duration and lack of long-term follow up. As a phase 2 clinical trial, there was no active comparator and a smaller sample size was also utilized.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Niikee Schoendorfer</name_or_title>
      <organization>University of Queensland</organization>
      <phone>0413122076</phone>
      <email>n.schoendorfer@uq.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

